We have located links that may give you full text access.
Journal Article
Validation Study
Computed tomography-derived assessments of regional muscle volume: Validating their use as predictors of whole body muscle volume in cancer patients.
British Journal of Radiology 2018 December
OBJECTIVE:: Evaluate the accuracy of CT-derived regional skeletal muscle volume (SMV) measurements to predict whole body SMV in patients with melanoma.
METHODS:: 148 patients with advanced melanoma who underwent whole body positron emission tomography/CT were studied. Whole body SMV was measured on CT and used as the reference standard. CT-derived regional measures of SMV were obtained in the thorax, abdomen, pelvis, and lower limbs. Models were developed on a discovery cohort (n-98), using linear regression to model whole body SMV as a function of each regional measure, and clinical factors. Predictive performance of the derived models was evaluated in a validation cohort (n = 50) by estimating the explained variation (R2 ) of each model.
RESULTS:: In the discovery cohort, all regional SMV measurements were significantly associated with whole body SMV [β1 range: 0.673-1.153, all p < 0.001)]. The magnitude of association was greatest for pelvic regional measurements {β = 1.153, [95% confidence interval (0.989, 1.317)]}. Prediction algorithms incorporating clinical variables and regional SMVs were developed to estimate whole body SMV from regional assessments. Using the validation cohort to predict whole body SMV, the R2 values for the pelvic, abdominal and thoracic regional measurements were 0.89, 0.86, 0.78.
CONCLUSION:: Regional measures of SMV are strong predictors of whole body SMV in patients with advanced melanoma.
ADVANCES IN KNOWLEDGE:: The first study utilizing whole body imaging as a reference standard validating the use of regional SMVs in cancer patients, including validating the use of regional SMVs outside of traditionally assessed areas.
METHODS:: 148 patients with advanced melanoma who underwent whole body positron emission tomography/CT were studied. Whole body SMV was measured on CT and used as the reference standard. CT-derived regional measures of SMV were obtained in the thorax, abdomen, pelvis, and lower limbs. Models were developed on a discovery cohort (n-98), using linear regression to model whole body SMV as a function of each regional measure, and clinical factors. Predictive performance of the derived models was evaluated in a validation cohort (n = 50) by estimating the explained variation (R2 ) of each model.
RESULTS:: In the discovery cohort, all regional SMV measurements were significantly associated with whole body SMV [β1 range: 0.673-1.153, all p < 0.001)]. The magnitude of association was greatest for pelvic regional measurements {β = 1.153, [95% confidence interval (0.989, 1.317)]}. Prediction algorithms incorporating clinical variables and regional SMVs were developed to estimate whole body SMV from regional assessments. Using the validation cohort to predict whole body SMV, the R2 values for the pelvic, abdominal and thoracic regional measurements were 0.89, 0.86, 0.78.
CONCLUSION:: Regional measures of SMV are strong predictors of whole body SMV in patients with advanced melanoma.
ADVANCES IN KNOWLEDGE:: The first study utilizing whole body imaging as a reference standard validating the use of regional SMVs in cancer patients, including validating the use of regional SMVs outside of traditionally assessed areas.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app